
- /
- Supported exchanges
- / US
- / NVCR.NASDAQ
Novocure Ltd (NVCR NASDAQ) stock market data APIs
Novocure Ltd Financial Data Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 622 M
- EBITDA: -153 508 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-05
- EPS/Forecast: -0.464
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data
Investing.com - H.C. Wainwright has reiterated a Buy rating and $38.00 price target on NovoCure Ltd. (NASDAQ:NVCR) following positive trial results for its cancer treatment. Currently trading at $17.8...


Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis ...

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of NovoCure Limited (NASDAQ:NV...

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) shares soared 5.3% in the last trading session to close at $18. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the s...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.